LSU Health New Orleans has signed a deal with a drug development company. The duo will perform research on marijuana to see if it can be used to treat Parkinson’s and Alzheimer’s disease.

Reports show that CB BioSciences will make an initial investment of $428,000 in order to support the research. CB BioSciences is a company based in Utah who specialize in the medical benefits of marijuana. Professor Chen, a neuroscience professor with LSU, has stated that he plans to use the THC found in marijuana to treat neurodegenerative diseases.

Cannabinoids also have potent antioxidant, anti-inflammatory and anti-cancer properties, and have been used to treat seizures and multiple sclerosis in the past. THC however can also trigger adverse affects, and until now there has been no way to prevent these effects. By combining the THC with COX-2 it seems, you can limit these effects, which could be very useful in treating other neurological disorders that have not been previously researched.

Chen hopes to explore whether or not THC and COX-2 can be used to delay Alzheimer’s as well as possibly treat those who already suffer from the disease. In addition to the initial investment by CB Biocience, LSU Health New Orleans will also have an equity stake in the company. They are currently trying to open an office in the New Orleans BioInnovation Centre on Canal St.

The program will be mutually beneficial, and the two companies are very excited to be collaborating with each other. With new and exciting discoveries ahead, there is a lot of anticipation from both companies and we can only hope that their research is successful. With marijuana becoming more and more useful for treating various medical conditions, there is no telling what other conditions it could help.